We read with interest the updated systematic review and meta-analysis by Boracchi and colleagues evaluating long-term secondary prevention with low-dose colchicine in patients with coronary artery disease (CAD) [1]. By reporting both individual endpoints and composite outcomes, and by separating acute coronary syndrome (ACS) from chronic coronary syndrome (CCS), the review offers a practical overview for clinicians. In the pooled analyses, colchicine was associated with fewer myocardial infarctions and fewer composite events, whereas cardiovascular and all-cause mortality remained neutral.
